Form 4: Organon & Co. CEO Kevin Ali Receives Stock Options and Restricted Stock Units
SEC Form 4 Filing
Organon & Co. CEO Kevin Ali was granted stock options and restricted stock units on March 29, 2024, according to a Form 4 filing with the SEC.
Summary
- On March 29, 2024, Kevin Ali, CEO of Organon & Co., was granted 146,276 restricted stock units (RSUs) and 599,128 stock options.
- The RSUs represent a contingent right to receive one share of Organon common stock for each RSU.
- The RSUs vest in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027.
- The stock options have an exercise price of $18.8 and also vest in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management and shareholder interests. The vesting schedule promotes long-term commitment.
Positives
- The grant of RSUs and stock options aligns the CEO's interests with those of the shareholders.
- The vesting schedule encourages long-term performance and retention of the CEO.
Industry Context
Executive compensation packages often include stock options and restricted stock units to incentivize performance and align management's interests with shareholders' interests. This grant is a typical component of executive compensation in publicly traded companies.
Comparison to Industry Standards
- Stock option and RSU grants are common compensation tools for CEOs in the pharmaceutical industry.
- The vesting schedule of three years is also a standard practice to encourage long-term commitment.
- Comparing the size of the grant to other pharmaceutical companies of similar market capitalization would provide a more detailed assessment of its competitiveness.
Stakeholder Impact
- Shareholders may view the grant positively as it incentivizes the CEO to improve company performance.
- Employees may see the grant as a sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 03/29/2024 | Date of transaction: Grant of restricted stock units and stock options |
| 03/29/2025 | First vesting date for RSUs and stock options |
| 03/29/2026 | Second vesting date for RSUs and stock options |
| 03/29/2027 | Third vesting date for RSUs and stock options; expiration date for RSUs and stock options |
| 04/02/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.